Comprehensive Review on Ebola (EBOV) Virus: Future Prospects

Author(s): Sajad Khan, Muhammad, Abdur Rauf*, Ahsan Khan, Muhammad Rizwan, Seema Patel, Haroon Khan, Adel M. Mahasneh, Mohammad S. Mubarak*.

Journal Name: Infectious Disorders - Drug Targets

Volume 18 , Issue 2 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Ebola virus (EBOV) was discovered for the first time in 1976. It belongs to the family Filoviridae, which causes hemorrhagic fever that could lead to death in a few days. West Africa faced a major outbreak where symptoms appeared in the form of chills, myalgia, fever, diarrhea, and vomiting, and the disease finally reached a severe state as a result of hemorrhagic complications and failure of multiple organs. EBOV spreads by contact with body fluids of an infected person such as blood, saliva, urine, and seminal fluid, and also spreads by a contact with contaminated surfaces. Viral infection depends on the virus and host defenses. When the virus invades the body, the immune system becomes activated in an attempt to neutralize it. However, if this fails, EBOV viral infection spreads and leads to impaired innate and adaptive immune responses and uncontrollable viral replication. Consequently, the symptomatic patient is isolated and various medicinal regimens such as BCX-4430n TKM- EBOV are used, to cure EBOV, though, a specific treatment is not available. Accordingly, the aim of the present review is to survey and summarize the recent literature pertaining to the outbreak of EBOV, systematic infection of the human body, along with transmission and treatment. In addition, the review also aims to identify areas that need more research and development in combatting this dangerous virus. In the meantime, it should be noted that there is no fully FDA approved drug to treat infections by this virus. Therefore, there is a pressing need to focus on drug discovery along with public awareness to effectively manage any outbreaks in the future.

Keywords: EBOV, Filoviridae, fever, infection, replication, transmission.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [96 - 104]
Pages: 9
DOI: 10.2174/1871526517666170817100828
Price: $58

Article Metrics

PDF: 36
PRC: 1